Longevity EvidenceNon-commercial
Anti-Amyloid Antibodies (Lecanemab and Donanemab) Are FDA-Approved with Disproportionate ARIA Risk in ApoE ε4 Homozygotes and Substantial Payer / Screening Complexity
Two anti-amyloid monoclonal antibodies are FDA-approved for early symptomatic Alzheimer disease; both produce modest slowing of decline in Phase 3 trials, both carry imaging abnormality risks that are higher in ApoE ε4 homozygotes, and rollout involves meaningful payer and clinic
- Type
- evidence-claim
- Domain
- h04_loss_of_proteostasis
- Grade
- A
- License
- CC BY-NC 4.0
- card_id
- L-023
- hallmarks
- h04_loss_of_proteostasis,h10_altered_intercellular_communication
- cluster
- clinical_translation
- primary_disease_area
- alzheimers
- evidence_tier
- A
- evidence_anchor_count
- 7
- intake_round
- R23
- intake_date
- 2026-05-26
- related_experts
- related_biomarkers
- related_interventions
- related_trials
- NCT03887455,NCT04437511
- collection_pages
- /research/interventions/anti-amyloid-antibodies,/research/clinical-translation/payer-and-access
LongProof Longevity Dynamic · LIGHT HOPE / x1000.ai · longevity.x1000.ai · 2026 · source
Read-only aggregated view. Longevity Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.